瑞舒伐他汀联合依折麦布治疗急性心肌梗死患者的疗效分析

陈志贤; 朱宗成; 盛晓东

doi:10.7619/jcmp.202018007

瑞舒伐他汀联合依折麦布治疗急性心肌梗死患者的疗效分析

江苏省常熟市第二人民医院心内科, 江苏常熟, 215500

详细信息

通讯作者:
朱宗成, E-mail: zongchengzhu@163.com

中图分类号: R542.2
计量
- 文章访问数: 562
- HTML全文浏览量: 92
- PDF下载量: 12
出版历程
- 收稿日期: 2020-07-24

Efficacy analysis of rosuvastatin combined with ezetimibe in the treatment of patients with acute myocardial infarction

Department of Cardiology, Changshu City Second People's Hospital in Jiangsu Province, Changshu, Jiangsu, 215500

摘要

摘要: 目的观察瑞舒伐他汀联合依折麦布治疗急性心肌梗死(AMI)行经皮冠状动脉介入治疗(PCI)患者的疗效。方法将120例AMI行PCI患者随机分为2组,每组60例。观察组采用瑞舒伐他汀联合依折麦布治疗,对照组采用瑞舒伐他汀治疗。随访12个月,比较2组生化指标［血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)］、炎症指标［超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)］、心功能参数［N末端B型利钠肽原(NT-proBNP)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)］、主要心血管不良事件发生情况以及冠状动脉病变情况。结果观察组术后3、6、9、12个月的TC、TG、LDL-C水平低于对照组, HDL-C水平高于对照组,差异均有统计学意义(P<0.05)。观察组术后3、6、9、12个月的hs-CRP、IL-6、TNF-α、NT-proBNP、LVEDD低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。观察组急性心肌梗死、心绞痛、支架内再狭窄和新发冠状动脉病变比率低于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀联合依折麦布治疗可有效降低AMI患者的血脂和炎症因子水平,改善患者心功能,降低冠状动脉病变和不良事件的发生率。
- 瑞舒伐他汀 /
- 依折麦布 /
- 经皮冠状动脉介入术 /
- 急性心肌梗死 /
- 左室射血分数
Abstract: Objective To observe the clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of patients with acute myocardial infarction(AMI)by percutaneous coronary intervention(PCI). Methods Totally 120 AMI patients with PCI were selected and randomly divided into two groups, with 60 cases in each group. Observation group was treated with rosuvastatin and ezetimibe, while control group was treated with rosuvastatin. After 12 months of follow-up, the biochemical indexes ［serum total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C)］, inflammatory indexes ［high sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)］, cardiac function parameters ［N-terminal pro-B-type natriuretic peptide(NT-proBNP), left ventricular end diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF)］, incidence of major adverse cardiovascular events and coronary artery disease were compared between two groups. Results The levels of TC, TG and LDL-C in the observation group were significantly lower than those in the control group at 3, 6, 9 and 12 months after operation, and the HDL-C level was significantly higher than that in the control group(P<0.05). The levels of hs-CRP, IL-6, TNF-α, NT-proBNP and LVEDD in the observation group were significantly lower than those in the control group at 3, 6, 9 and 12 months after operation, and the LVEF was significantly higher than that in the control group(P<0.05). The incidence rates - of acute myocardial infarction, angina pectoris, in-stent restenosis and new coronary artery disease in the observation group were significantly lower than those in the control group(P<0.05). Conclusion Rosuvastatin combined with ezetimibe can effectively reduce the levels of blood lipid and inflammatory factors in AMI patients, improve cardiac function, and reduce the incidence rates of coronary artery disease and adverse events.
- rosuvastatin /
- ezetimibe /
- percutaneous coronary intervention /
- acute myocardial infarction /
- left ventricular ejection fraction

HTML全文

参考文献(16)

SAKALAKI M, BARYWANI S, ROSENGREN A, et al. Determinants of suboptimal long-term secondary prevention of acute myocardial infarction: the structural interview method and physical examinations[J]. BMC Cardiovasc Disord, 2019, 19(1): 243-251.

李丽亚, 许丁. 依折麦布与阿托伐他汀联用治疗血脂控制不佳老年冠心病的临床观察[J]. 中国社区医师, 2020, 36(2): 69-70.

MACH F, BAIGENT C, CATAPANO A L, et al. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Revista Española De Cardiol Engl Ed, 2020, 73(5): 403-411.

FARNIER M, JONES P, SEVERANCE R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial[J]. Atherosclerosis, 2016, 244: 138-146.

梁春. 强化降脂和抗炎“双达标”防治动脉粥样硬化性心血管疾病: 虚拟还是现实[J]. 临床心血管病杂志, 2019, 35(9): 775-776.

KUMAR B, SHAH M A A, KUMAR R, et al. Comparison of atorvastatin and rosuvastatin in reduction of inflammatory biomarkers in patients with acute coronary syndrome[J]. Cureus, 2019, 11(6): e4898.

RIDKER P M, DANIELSON E, FONSECA F A H. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. J Vasc Surg, 2009, 49(2): 534-539.

白艳辉, 张春来, 冯玉斌, 等. 冠心病二级预防中降脂药物服用及血脂水平控制危险因素调查研究[J]. 中国全科医学, 2018, 21(8): 970-974.

ZHAO S, WANG Y, MU Y, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study(DYSIS)[J]. Atherosclerosis, 2014, 235(2): 463-469.

陈炎, 陈亚蓓, 陶荣芳. 《2016年中国成人血脂异常防治指南》内容介绍[J]. 中国实用内科杂志, 2017, 37(S1): 38-42.

刘志, 李静, 高敬, 等. 老年急性冠状动脉综合征患者阿托伐他汀联合依折麦布对比双倍剂量阿托伐他汀疗效研究[J]. 中华老年心脑血管病杂志, 2017, 19(1): 5-8.

HUANG Z, LI Q, YE W, et al. Efficacy and safety of ezetimibe in combination with atorvastatin for acute coronary syndrome patients accompanied with type 2 diabetes: a single-center, non-randomized cohort study[J]. Chem Pharm Bull(Tokyo), 2019, 67(5): 419-425.

GUERIN M, SILVAIN J, GALL J, et al. Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol, 2018, 72(25): 3259-3269.

PRATI F, MARCO V, PAOLETTI G, et al. Coronary inflammation: why searching, how to identify and treat it[J]. Eur Heart J Suppl, 2020, 22(Suppl E): E121-E124.

赵星星, 贾永平, 范春雨, 等. 阿托伐他汀联合依折麦布对冠心病患者脂代谢指标及炎症反应的影响[J]. 中国药物与临床, 2019, 19(4): 590-592.

吴睿. 依折麦布联合阿托伐他汀对急性心肌梗死患者炎性反应及心功能的影响[J]. 当代医学, 2020, 26(20): 35-37.